secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q/C TECHNOLOGIES, INC. (QCLS)
CIK:        0001321834
Form:       8-K
Filed at:   2023-04-12T23:59:59+00:00
Accession:  0001493152-23-011941
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MyMD doses 37 of 40 patients in Phase 2 trial of MYMD-1 for sarcopenia/frailty; no safety issues
--------------------------------------------------------------------------------

- Safety Review Committee confirms no safety/toxicity issues with first 30 patients; unanimous vote to escalate to final dose level.
- 37 of 40 total patients randomized and dosed across four cohorts; only 3 patients away from dosing final patient.
- Phase 2 double-blind, placebo-controlled study targets reduction of chronic inflammatory markers (IL-6, sTNFR-1) in patients aged 65+.
- No FDA-approved treatments currently exist for sarcopenia/frailty; aging disorders market estimated at $600B by 2025.
- Company planning early-stage trials for rheumatoid arthritis with MYMD-1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223011941/0001493152-23-011941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223011941/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-011941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer